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Abstract: 
Post-translational modifications (PTMs) of transcription factors have emerged as an important 
regulatory mechanism in eukaryotes. PTMs can modulate the function of a protein, and 
inappropriate modifications can result in diseases. A protein can become post-translationally 
modified in several different ways. It can range from a small modification, such as 
phosphorylation, to more large modifications, such as conjugation with small polypeptides like 
ubiquitin or SUMO.  
Gcn4 is a transcriptional activator that regulates amino acid biosynthetic genes in yeast. Gcn4 is 
expressed under amino acid starvation conditions, and its degradation depends on phosphorylation, 
by either Pho85 or Cdk8, which triggers its ubiquitination and subsequent proteolysis by the 26S 
proteasome. Previous studies showed that Gcn4 becomes sumoylated at two Lys residues (K50, 
58), specifically after binding to target gene promoters. However, it is not clear how promoter-
associated sumoylation of Gcn4 is coordinated with its phosphorylation and ubiquitination as part 
of a regulatory cascade of PTMs.  
To address this, we examined Gcn4 modifications in individual sumoylation-deficient mutant, 
phosphorylation-site mutant and ubiquitination-impaired Gcn4 strains. Our results indicate that 
Gcn4 sumoylation is not dependent on its prior phosphorylation or ubiquitination; however, some 
degree of Cdk8-mediated phosphorylation and ubiquitination is dependent on sumoylation. 
Furthermore, we generated a hyper-sumoylated form of Gcn4 that shows significantly reduced 
occupancy on target DNA, which is dependent on Cdk8. Our results suggest that SUMO 
modification of promoter-bound Gcn4 triggers its removal by stimulating Cdk8-mediated 
phosphorylation and subsequent ubiquitination.  
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Together, this study contributes to the understanding of post-translational modifications of Gcn4, 
and such information could reveal new targets for directed therapy of diseases or cancer resulting 
from deregulated signaling pathways. 
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Chapter 1: Introduction 
Gene expression is a highly complex and tightly regulated process that requires an ensemble of 
factors to properly initiate transcription from a DNA template to generate messenger RNA 
(mRNA), which can then be translated into a protein. In eukaryotes, appropriate regulation of 
transcription of protein-encoding genes, mediated by RNA polymerase II (RNAP II) in 
conjunction with a complex array of general transcription factors (GTFs), is essential for normal 
cell growth and function. Through the action of transcription factors, various cells containing the 
same genome can function differently, and the functions of these transcription factors can be 
regulated by post-translational modifications (PTMs), such as phosphorylation, ubiquitination, and 
sumoylation (Struhl, 1993). For example, the yeast transcriptional activator of amino acid 
biosynthetic genes Gcn4, becomes sumoylated during target gene activation which facilitates its 
subsequent removal from promoters (Rosonina et al., 2012). Defects in transcriptional regulation 
can lead to developmental problems or to diseases such as cancer (Audic and Hartley, 2004). 
Therefore, it is essential to understand the mechanisms of transcription and how it is regulated. 
 
1.1 Transcriptional Initiation (Pre-initiation Complex Assembly):  
The transcription of eukaryotic RNAP II-dependent genes involves a cascade of events that 
generally begins with the sequence-specific binding of an activator protein to the regulatory 
elements proximal to the gene's promoter region (Morse, 2007). In yeast, these gene-specific 
regulatory elements are known as upstream activating sequences (UAS), while in higher organisms 
they are known as enhancers, which can be situated hundreds or thousands of base-pairs (bp) from 
the gene’s transcriptional start site (TSS) (Buchman and Kimmerly, 1988). Binding of 
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transcriptional activators to their target elements initiates the sequential recruitment of GTFs, 
RNAP II and the Mediator complex which assemble to form a functional pre-initiation complex 
(PIC). The PIC is essential for directing specific TSS selection and transcription initiation (Thomas 
and Chiang, 2006). 
Transcriptional activators direct PIC assembly on the core promoter, a sequence of approximately 
40-120 bp upstream of the TSS in the yeast Saccharomyces cerevisiae, whereas in mammals it is 
located around 25-30 bp upstream of the TSS (Smale and Kadonaga, 2003; Yang et al., 2007). The 
core promoter often contains a number of sequence specific motifs including the TATA box, the 
initiator (INR), TFIIB-recognition element (BRE) and downstream promoter elements (DPE) 
(Smale & Kadonaga 2003; Juven-Gershon & Kadonaga 2010) (Figure 1). Most yeast core 
promoters do not contain a consensus TATA box, but  instead contain ‘TATA-like’ sequences that 
differ from the TATA box consensus by up to 2 bases (Basehoar et al., 2004; Rhee and Pugh, 
2012).   
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Figure 1. Schematic of the structure and sequence of core promoter elements in eukaryotes. 
(A) A simple core promoter containing a TATA box and initiator (INR) element, with upstream 
activation sequence (UAS) shown, as found on in yeast (unicellular eukaryotes). (B) A complex 
core promoter containing a TATA box, INR, TFIIB-recognition element (BRE), and downstream 
promoter elements (DPE) that is typically found in mammals (higher eukaryotes). An enhancer 
element is also shown. Also indicated are the approximate position of the elements relative to the 
TSS (above) and their consensus sequences (below). Any particular core promoter may contain 
all, some or none of these motifs. 
 
 
A 
 
B 
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In general, the first step in canonical PIC assembly is the sequence-specific binding of TFIID, 
comprised of the TATA-binding protein (TBP) and a dozen or so evolutionarily conserved 
RNAPII-specific TBP-associated factors (TAFs), to the TATA box (Klein and Struhl, 1994; 
Nikolov et al., 1995) (Figure 2). This binding induces a dramatic bend in the DNA structure. 
TFIIA and TFIIB are then recruited, further stabilizing the interaction between TBP and promoter 
DNA (Flores et al., 1991; Nikolov et al., 1995). TFIIB binds to both TBP and DNA leading to the 
recruitment of the RNAP II–TFIIF complex (Lee and Hahn, 1995). RNAP II and TFIIF enter the 
complex together, with TFIIF ensuring the specific and stable binding of the polymerase to DNA 
(Deng and Roberts, 2007). In the presence of TFIIB and TFIIF, RNAP II orients the DNA template 
selecting the transcription start site (Bushnell et al., 2004). Finally, TFIIE and TFIIH are recruited 
to form the transcriptionally competent PIC and, together with the help of RNAP II, catalyze 
promoter melting and conversion from transcription initiation to elongation (Buratowski et al., 
1989; Martinez, 2002; Deng and Roberts, 2007). Upon initiation of transcription, RNAP II moves 
along the DNA strand, leaving TFIID and TFIIA bound to the TATA box which can then facilitate 
the binding of additional RNAP II molecules (Van Dyke et al., 1989; Zawel et al., 1995). 
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Figure 2: Schematic of the RNAPII pre-initiation complex (PIC) at the core promoter. PIC 
formation occurs by the stepwise recruitment of the general transcription machinery. First, TBP (a 
component of TFIID) binds to the promoter and recruits TFIIA and TFIIB. Then RNAP II and 
TFIIF are recruited by TFIIB. To complete the PIC assembly, RNAP II recruits TFIIE, which 
further recruits TFIIH. 
 
 
1.2 Mediator Component Cdk8: 
Mediator is a large, multi-subunit complex that functions as an intermediate between 
transcriptional activators and the PIC components to coordinate transcription (Cantin et al., 2003; 
Biddick and Young, 2005; Conaway et al., 2005). Almost all yeast Mediator subunits have 
homologs in mammals ((Biddick and Young, 2005). However, human Mediator is more complex 
than its yeast counterpart (Conaway et al., 2005). Mediator may exist in at least two forms: a 
smaller “core Mediator complex” form and a larger “CDK8 Mediator complex” form. The core 
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Mediator complex consists of 25 subunits and is 1.2 MDa in size, while the CDK8 Mediator 
complex contains an additional CDK module and is ~ 2 MDa in size (Wang et al., 2001). 
Cdk8, a cyclin-dependent kinase and component of the CDK Mediator complex, is associated with 
transcriptional regulation from yeast to mammals (Manning et al. 2002; Malumbres et al. 2009). 
Within the Mediator complex, Cdk8 is part of the CDK module which is composed of Cdk8, Cyclin 
C, Med12 and Med13  (Borggrefe et al., 2002; Galbraith et al., 2010) (Figure 3). Cdk8 
phosphorylates several targets, including RNAP II and transcriptional factors (Borggrefe and 
Davis, 2002; Nemet et al., 2014).  
 
 
Figure 3. Cdk8 connections map. CDK8 directly interacts with Cyclin C, Med12 and Med13 
which form CDK module that connects to the core Mediator through MED13. Through the core 
mediator, the CDK module interacts with RNAP II and multiple GTFs. The CDK module targets 
activators directly or through the core mediator.  
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The functional significance of these Cdk8-mediated phosphorylation events differ depending on 
the target protein. Studies revealed that Cdk8 responds to numerous intracellular signaling 
pathways and plays both positive and negative roles in transcriptional regulation (Hengartner et 
al., 1998; Nemet et al., 2014). For example, Cdk8-dependent phosphorylation of Gal4 is essential 
for activation of galactose-inducible genes in yeast (Hirst et al., 1999), while in mammals, Cdk8 
positively regulates the p53 pathway, the serum response network, and Sip4-dependent 
transcription (Vincent et al. 2001; Donner et al. 2007; Donner et al. 2010). Furthermore, Cdk8 
dependent phosphorylation of histone H3 subsequently stimulates H3K14 acetylation and 
transcription (Meyer et al., 2008). However, several mechanisms of negative regulation of 
transcription by Cdk8 are also known. For example, Cdk8 phosphorylates the CTD of RNAP II 
and prevents the interaction of RNAP II with the core Mediator complex, thereby repressing 
transcription (Hengartner et al. 1998; Borggrefe & Davis 2002). Additionally, Cdk8-dependent 
phosphorylation of Cdk7 and Med13 is involved in the inhibition of transcription (Egly and Coin, 
2011). Besides transcriptional activation and repression, Cdk8 is also involved in protein turnover. 
For example, the stability and activity of transcriptional activators, Gcn4 and Phd1, are regulated 
by Cdk8 dependent phosphorylation, which ultimately signals their rapid degradation (Chi et al., 
2001;  Raithatha et al., 2012; Rosonina et al., 2012;). 
 
1.3 Transcriptional Activators: 
Transcriptional activators are generally sequence-specific DNA binding proteins responsible for 
the recruitment of multiple complexes that comprise the transcriptional machinery, to the promoter 
in order to turn on gene expression. Most eukaryotic gene expression is highly regulated by 
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activators during development or in response to changes in the cellular environment (Ptashne, 
1988). Malfunctioning transcriptional activators are associated with a significant percentage of 
human diseases, including cancers. For example, more than 50% of cancer related cases are 
associated with mutations in the transcriptional activator p53 (Hainaut and Hollstein, 2000).  
In general, activators have a modular structure, typically comprising a DNA-binding domain 
(DBD) and one or more activation domains (AD). Normally, the DBDs consist of a wide variety 
of structural folds including zinc fingers, zinc clusters, leucine zippers and the helix-turn-helix 
motif that interact with DNA with high specificity (Marmorstein et al., 1992; Luscombe et al., 
2000). DBDs are responsible for binding to their cognate DNA sequence in the promoter of target 
genes. In contrast, since ADs do not share recognizable motifs or structure among eukaryotes, they 
are often classified depending on their overall amino acid composition: as Pro-rich, Gln/Asn-rich, 
or acid rich ADs ( Hoy et al., 1993; Gerber et al., 1994; Luscombe et al., 2000). Activation domains 
usually bind to coactivators which initiates a cascade of events including targeted chromatin 
remodeling and stimulation of both the PIC formation and transcription elongation that leads to 
productive transcription (Kobayashi et al., 1995; Thomas and Chiang, 2015) (Figure 4). The 
function of most ADs is conserved among eukaryotes, even though DNA-binding sequences and 
some key activator targets, such as co-activators, are not. In addition, ADs are regulated by post-
translational modifications such as ubiquitination, acetylation, phosphorylation, sumoylation, 
methylation and glycosylation which further regulate the timing of transcriptional activators on 
target gene promoters ( Chi et al., 2001; Lipford et al., 2005).  
 
9 
 
   
  
 
 
 
 
          
Figure 4. General model of Activator-Mediated Stimulation of PIC Assembly. (A) 
Transcriptional activators recruit the transcriptional machinery to a target gene promoter. (B) An 
activator is usually composed of at least two modular domains, an activation domain (AD) and a 
DNA-binding domain (DBD). 
 
Generally, strong transcriptional activators are very unstable proteins due to ubiquitin (Ub)-
mediated proteolysis through the 26S proteasome. For example, the yeast transcription factors 
Gcn4, Gal4 and Ino2/4 and the mammalian transcription factors p53, Jun, Myc and Fos are all 
short-lived proteins that are regulated by Ub-mediated proteolysis (Chowdary et al., 1994; Treier 
et al., 1994; Salghetti et al., 1999; Lipford et al., 2005). Ub-mediated proteolysis destroys its targets 
with extreme precision since destruction by the 26S proteasome generally depends on recognition 
of polyubiquitination of target proteins (Kornitzer et al., 1994; Salghetti et al., 2000). However, 
studies have shown that in the majority of cases, interactions of the activation domains of activators 
with the basal transcriptional machinery are necessary for their destruction. Studies also revealed 
A. B. 
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that numerous transcriptional activators are destroyed because of their ability to initiate 
transcription (Salghetti et al., 2000). This is thought to be important for allowing transcription 
factor turnover on promoters, which allows gene activation levels to reflect transcription factor 
abundance (Salghetti et al., 2000). However, not all activation domains are capable of being 
targeted by Ub-mediated proteolysis. For example, activation domains that are rich in Pro or Gln 
residues do not signal protein turnover, whereas acidic residue-rich activation domains often do 
signal Ub-mediated destruction ( Rogers et al., 1986; Rechsteiner, 1988; Salghetti et al., 2000).  
 
1.4 Sumoylation: 
Sumoylation is a conserved and reversible post-translational modification that has been implicated 
in processes ranging from transcriptional regulation to DNA damage repair to the immune 
response (Zhao, 2007; Cubeñas-Potts and Matunis, 2013). Similar to ubiquitination, protein 
sumoylation involves the covalent and reversible attachment of the small ubiquitin-like modifier 
(SUMO) peptide to specific Lys residues, usually determined by a consensus sumoylation motif, 
ΨKxE (where Ψ is a large hydrophobic residue, and x is any amino acid), on target proteins ( 
Rodriguez et al., 2001; Geiss-Friedlander and Melchior, 2007).  
SUMO peptides are small (~12 kDa) and share a similar three-dimensional structure with ubiquitin 
(Geiss-Friedlander and Melchior, 2007) (Figure 5). However, they share less than 20% amino acid 
sequence identity with ubiquitin and are different in their overall surface-charge distribution. In 
addition, SUMO proteins carry an unstructured stretch of 10-25 amino acids at their N-termini that 
is not found in ubiquitin. SUMO proteins are conserved in all eukaryotes; budding yeast express a 
single SUMO isoform, encoded by the essential SMT3 gene, whereas three main isoforms are 
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found in mammalian cells, SUMO-1, SUMO-2 and SUMO-3 (Geiss-Friedlander and Melchior, 
2007; Meluh and Koshland, 1995). SUMO -2 and SUMO-3 are almost 95% identical and are often 
collectively referred to as SUMO-2/3, whereas SUMO-1 is approximately 48% identical to 
SUMO-2 and 46% identical to SUMO-3 (Miteva et al., 2000; Saitoh, 2000). All three main  
mammalian SUMO isoforms are about 45% identical to the yeast Smt3 protein (Wang and Dasso, 
2009). SUMO-1 does not form polysumoylated chains whereas the mammalian SUMO-2/3 and 
yeast Smt3 do (Tatham et al., 2001).  
 
 
Figure 5: Structural comparison of Human SUMO-1 and Ubiquitin proteins. Ribbon diagram 
of the 3D structural similarity of SUMO-1 (left; (Bayer et al., 1998)) and Ubiquitin (right; (Vijay-
Kumar et al., 1987)). Secondary structure elements, such as sheets (in green) and helices (in red) 
are presented. Unlike ubiquitin, the SUMO protein has an N-terminal extension.   
 
 
Similar to ubiquitination, the sumoylation pathway involves a cascade of enzymatic activities 
involving E1-activating enzymes, a sole E2-conjugating enzyme, and in some cases, an E3-ligating 
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enzyme (Miteva et al., 2000) (Table 1). Generally, SUMO is synthesized as an inactive molecule. 
In the first step, a SUMO specific protease (Ubiquitin-like specific protease (Ulp) in yeast or 
SENtrin-specific protease (SENP) in humans) cleaves the C-terminus of the nascent SUMO 
peptide to expose a di-Gly motif at its C-terminus for conjugation (Figure 6) (Mukhopadhyay and 
Dasso, 2007). This step converts the precursor form of SUMO polypeptide to a mature form, which 
is then activated in an ATP-dependent reaction in which its C-terminal Gly residue forms a 
thioester conjugate with a Cys residue in the active site of the heterodimeric SUMO activating 
enzyme E1 (Aos1/Uba2in yeast and Sae1/Sae2 in mammals) (Johnson et al., 1997; Lois and Lima, 
2005). Through an intermolecular thiol-transfer reaction, the activated SUMO is subsequently 
transferred to the E2 conjugating enzyme, Ubc9. From there, SUMO is conjugated to a specific 
Lys residue on a substrate protein via an isopeptide bond (Bernier-Villamor et al., 2002). Several 
SUMO E3 ligases, such as Siz1, Siz2 and Mms21 in yeast and several in mammalian cells, have 
been shown to stimulate the transfer of SUMO from Ubc9 to specific substrates (Johnson and 
Gupta, 2001; Zhao and Blobel, 2005).  
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Figure 6: The Sumoylation pathway. Immature SUMO undergoes maturation through cleavage 
by a SUMO-specific protease to disclose its C-terminal Gly-Gly motif (Step 1). The mature SUMO 
protein is then activated by the E1 heterodimer in an ATP-dependent reaction (Step 2). The 
activated SUMO is then transferred to an E2 enzyme, UBC9 (Step 3). With the help of E3 ligases, 
Ubc9 then transfers the SUMO peptide to a specific Lys residue of the target protein (Step 4). 
Also, SUMO modifications can be removed from conjugated species by the action of SUMO 
proteases (Step 5).  
(Adapted from Dasso, 2008) 
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Table 1: SUMO proteins and known enzymes of the sumoylation pathway in yeast and mammals  
Proteins /Enzymes Yeast 
(S. cerevisiae) 
Mammals 
(H. sapiens) 
SUMO Smt3 SUMO1, SUMO2 and SUMO3 
SUMO E1  
(activating enzyme) 
Aos1, Uba2 Sae1, Sae2 
SUMO E2 
(conjugating enzyme) 
Ubc9 Ubc9 
SUMO E3 
(ligating enzyme) 
Siz1, Siz2, Mms21 
and Zip3 
PIAS1, PIAS3, PIASxα, PIASxβ, 
PIASy, RanBP2, TOPORS, PC2, 
HDAC4 and Mms21 
SUMO protease Ulp1, Ulp2 
SENP 1, SENP 2, SENP 3, SENP 5, 
SENP 6 and SENP 7. 
 
 
SUMO modifications can be removed from substrates by SUMO-specific proteases, which have 
isopeptidase activity (Mukhopadhyay and Dasso, 2007). Several SUMO-specific proteases have 
been identified, including Ulp1 and Ulp2 in yeast, and the SENP family in humans (Li and 
Hochstrasser, 1999; Yeh et al., 2000). Therefore, sumoylation is a highly dynamic process in which 
its steady-state levels are tightly regulated by the complex interplay of the SUMO E1, E2, E3, and 
proteolytic enzymes. However, dysregulation of sumoylation is associated with a number of 
different diseases, including Huntington's, Alzheimer's, Parkinson's and various cancers (Steffan, 
2004; Martin et al., 2007). For example, general sumoylation levels are significantly elevated in 
metastatic breast cancer cells, and both Ubc9 and SUMO protease expression levels are altered in 
a large number of tumors (Mo and Moschos, 2005; Cheng et al., 2006; Subramonian et al., 2014). 
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The consequences of protein sumoylation are diverse, and unlike ubiquitination, sumoylation has 
not been found to directly signal protein degradation. In some cases, SUMO modifications 
compete with ubiquitin for a particular Lys acceptor site, thereby preventing subsequent 
ubiquitination and eventual degradation by the proteasome (Desterro et al., 1998; Hoege et al., 
2002). For instance, SUMO-modification of IkBa (inhibitor of nuclear factor kB alpha) blocks its 
ubiquitination at a specific Lys residue (K21), which eventually inhibits ubiquitin-dependent 
degradation by the proteasome (Desterro et al., 1998). Alternatively, SUMO-modification can lead 
to ubiquitination through recognition by SUMO-targeted ubiquitin E3 ligases (STUbLs), which 
recognize polysumoylated target proteins through their SUMO-interaction motifs (SIMs) (Prudden 
et al., 2007; Geoffroy and Hay, 2009). For instance, sumoylation of acute promyelocytic leukemia 
(PML) protein (specifically at K160 residues) triggers its recognition by the RNF4 STUbL, which 
then facilitates PML polyubiquitination and proteasome-dependent degradation (Lallemand-
Breitenbach et al., 2008).  
 
1.5 Sumoylation and Transcription: 
Sumoylation has emerged as a fundamental regulatory cellular mechanism that targets a variety of 
proteins involved in an array of processes including cell cycle regulation, transcription, 
chromosome stability, and subcellular localization (Geiss-Friedlander and Melchior, 2007; Zhao, 
2007). Although sumoylated proteins are found throughout the cell, the largest classes of SUMO 
targets are involved in transcription (Makhnevych et al., 2009; Cubeñas-Potts and Matunis, 2013). 
Fittingly, many transcriptional activators, repressors, co-regulators and GTFs have been identified 
as SUMO targets in both yeast and mammalian cells ( Zhao, 2007; Cubeñas-Potts and Matunis, 
2013; Raman et al., 2013). The effects of SUMO modification on transcription factor activity are 
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diverse. The sumoylation of some transcription factors, such as TCF-4 (T-cell factor-4) and Ikaros, 
is associated with an increase in transcription (Yamamoto et al. 2003; Gómez-del et al. 2005). 
However, in an overwhelming majority of cases, SUMO modification is associated with an 
inhibition in transcription, which can be accomplished by different SUMO-mediated mechanisms. 
For the transcription factor Elk-1, its sumoylation stimulates the recruitment of the histone 
deacetylase HDAC-2, which reduces histone acetylation and thereby inhibits transcription (Yang 
and Sharrocks, 2004). SUMO modifications can also inhibit transcription by regulating nuclear 
localization of some transcription factors, such as SATB2 and c-Myb (Morita et al., 2005). In 
yeast, sumoylation regulates the promoter occupancy of the transcriptional activator Gcn4 and the 
repressor Tup1, to reduce transcription of target genes ( Rosonina et al., 2012; Ng et al., 2015).  
 
1.6 Gcn4: 
Gcn4, a yeast transcriptional activator and member of the AP-1 transcription factor family, 
regulates the expression of genes involved in amino acid or purine biosynthesis in response to 
amino acid deficiency, purine insufficiency, glucose limitation, high salinity or treatment with 
sulfometuron methyl (SM), which induces amino acid starvation (Struhl 1987; Yoshida et al. 1998; 
Goossens et al. 2001; Hinnebusch & Natarajan 2002). The Gcn4 (~32 kDa) protein is composed 
of 281 amino acids, containing two tandem N-terminal acidic activation domains (ADs) and a C-
terminal basic leucine zipper DNA binding domain (DBD) (Hope and Struhl, 1987). Through its 
DBD, Gcn4 binds specifically to the consensus sequence ‘TGACTC’ of amino acid biosynthesis 
gene promoters, such as ARG1, as a homodimer (Ellenberger et al., 1992) (Figure 7). Its AD then 
interacts with coactivator proteins thereby initiating a cascade of events leading to the formation 
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of the PIC and thus triggering transcription during amino acid deprivation  (Ptashne & Gann 1997; 
Brzovic et al., 2011). 
Although the Gcn4 protein plays an important role in many biological functions, its regulation in 
response to amino acid starvation has been studied in detail. Studies showed that under normal 
growth conditions, Gcn4 is an unstable protein due to its efficient proteasomal degradation 
mediated by phosphorylation and ubiquitination (Kornitzer et al., 1994; Lipford et al., 2005). Its 
half-life ranges from approximately two minutes under growth in rich medium to 10 minutes under 
amino acid starvation conditions (Shemer et al., 2002). In addition to phosphorylation and 
ubiquitination, Gcn4 is also modified by SUMO post-translational modifications (Rosonina et al., 
2010). 
 
Figure 7. Structure of the Gcn4 bZIP domain bound to DNA. NMR structure of the Gcn4 bZIP 
domains (blue) that binds to the major groove of a specific DNA sequence (gray) as a homodimer. 
The dimer is formed through hydrophobic interactions between leucine residues in the two 
polypeptide chains (PDB ID: 1YSA).  
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1.7 Regulation of Gcn4: 
Gcn4 is highly regulated. Two pathways are involved in Gcn4 degradation through ubiquitin-
mediated proteolysis, each involving a different cyclin-dependent kinase (CDK), Pho85 or Cdk8 
(Meimoun et al., 2000; Chi et al., 2001)(Irniger and Braus, 2003). Both kinases phosphorylate 
Gcn4 at one or more potential CDK phosphorylation sites (S17, T61, T105, T165 and S218) 
(Meimoun et al., 2000; Chi et al., 2001; Irniger and Braus, 2003) (Figure 8). In the presence of 
sufficient amino acids, Pho85 binds the cyclin Pcl5 and phosphorylates Gcn4 regardless of whether 
it is promoter-bound or unbound, whereas Cdk8, a component of the Mediator complex associated 
with RNAP II, phosphorylates promoter-bound Gcn4 independently of amino acid availability 
(Figure 9) (Meimoun et al. 2000; Chi et al. 2001).  
 
Figure 8: A schematic diagram of Gcn4 structure. Gcn4 is composed of three modular domains, 
two activation domains (ADs) and a bZIP dimerization and DNA-binding domain (DBD). It 
possesses five consensus CDK phosphorylation sites, (S17, T61, T105, T165 and S218) and two 
sumoylation sites (K 50, 58) that are indicated by encircled P and S respectively. 
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Figure 9: Regulation of promoter-bound or unbound Gcn4 by CDKs: Pho85 and Cdk8. (A) 
Both kinases target Gcn4 for phosphorylation, and (B) Phosphorylated Gcn4 is then specifically 
recognized by Cdc4, which further recruits Skp1, Rbx1, Cdc53 and the Ub-conjugating enzyme 
Cdc34. Eventually, Cdc34 transfers Ub to Lys residues in Gcn4 and triggers Ub-mediated 
proteasomal degradation. 
 
 
In both pathways, phosphorylation targets Gcn4 for ubiquitination and subsequent degradation 
through the 26S proteasome (Lipford et al., 2005). The ubiquitination of Gcn4 is mediated by the 
specific multi-subunit ubiquitin ligase complex SCF, comprising Skp1, Cdc53 (or cullin) and F-
box-containing Cdc4, with the additional association of the ubiquitin-conjugating enzyme Cdc34 
(Meimoun et al. 2000; Chi et al. 2001). Cdc4 recognizes phosphorylated Gcn4 and recruits it into 
A. 
B. 
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the SCFCdc4 Ub– ligase complex, whereas Cdc34 transfers Ub to Lys residues in Gcn4 (Meimoun 
et al., 2000).  
In addition to phosphorylation and ubiquitination, Gcn4 becomes sumoylated on two Lys residues 
(K50, 58) specifically after binding to target gene promoters (Rosonina et al., 2012). ChIP 
experiments performed in yeast strains expressing a mutant, non-sumoylatable form of Gcn4 
showed that blocking Gcn4 sumoylation resulted in higher occupancy levels on target promoters 
suggesting that SUMO modifications of Gcn4 are important for its efficient clearance from target 
promoters (Rosonina et al., 2012). 
 
1.8 Objectives: 
We hypothesize that SUMO modification of Gcn4 takes place after it binds DNA, which then 
stimulates the removal of the activator from induced promoters by facilitating its Cdk8 and 
ubiquitin-mediated degradation after it has acted in transcriptional activation. To address this 
model, this project aimed to identify the determinants of Gcn4 sumoylation. Specifically, the 
project (1) examines how promoter-associated sumoylation of Gcn4 is coordinated with its 
phosphorylation and ubiquitination as part of a regulatory cascade of PTMs, and (2) provides 
further evidence that sumoylation of Gcn4 acts to enhance its removal from target promoters, after 
it has acted in transcriptional activation. To accomplish this, we determined how Gcn4 
phosphorylation and ubiquitination are affected by blocking its sumoylation, and vice versa. 
Additionally, we examined the effect of blocking ongoing transcription on Gcn4 sumoylation to 
determine whether Gcn4 sumoylation is dependent on its ability to activate transcription. Finally, 
we generated a SUMO-Gcn4 fusion protein and examined the effects “permanently sumoylating” 
Gcn4 on its clearance from target promoters. 
21 
 
The results of this project shed light on the detailed mechanism by which Gcn4 is regulated on 
target promoters through a cascade of interdependent PTMs. 
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Chapter 2: Materials and Methods 
2.1 Yeast Strains and Plasmids:  
Yeast (Saccharomyces cerevisiae) strains used in this study are listed in Appendix Table 1. Strains 
were derived from either the S288C or W303 background strains, and all chromosomally Gcn4-
6HA-tagged yeast strains were generated by homologous recombination as previously described 
(Rosonina et al., 2010). The presence of the 6HA-tagged was then confirmed by PCR and Western 
blot analysis with anti-HA antibody.  
The pGcn4-6HA plasmid was generated by amplifying Gcn4 with 1 kb each of flanking upstream 
and downstream genomic sequence and subsequently cloning the PCR product into the URA3-
marked CEN vector pRS316. A site-directed, PCR-based mutagenesis approach was employed to 
generate the mutagenic plasmids for Gcn4 activation mutant strains (Primers are listed in 
Appendix Table 2). 
 
2.2 Yeast Media and Growth Conditions:  
Yeast cultures (10 -25 mL) were grown at 30°C (unless otherwise specified) in either Synthetic 
Complete (SC; 0.17% YNB, 0.5% ammonium sulfate, and 2% glucose) media or SC dropout 
media based on the auxotrophic markers of the plasmids or strains used in experiments, to an 
optical density A595 (O.D.) of 0.6-0.8, then induced for 20 min (otherwise indicated) with SM 
(Sigma) at a final concentration of 0.5ug/ml. 
For proteasome inhibition, the method of Liu et al was used (Liu et al., 2007). Strains were grown 
overnight in special SC medium (containing L-proline 0.1%) as sole nitrogen source instead of 
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ammonium sulfate). In the morning, samples were diluted to an A590 (O.D.) of 0.5 in the same 
medium plus SDS to a final concentration of 0.03%, and grown for three hours. Samples were then 
treated with the proteasome inhibitor MG132 (75μM) for 45 min followed by 20 min in SM (0.5 
μg/mL) to induce Gcn4 expression.  
 
2.3 Spot Assay:  
Cells were grown in appropriate liquid medium overnight, and densities determined on the 
following morning. Approximately 10,000 cells of each strain were spotted side-by-side in the first 
position, and serial five-fold dilutions were spotted in the adjacent positions, on appropriate solid 
medium plates. All plates were incubated at 30˚C (unless otherwise stated) and images were 
recorded daily for up to three days.  
 
2.4 Immunoprecipitation (IP): 
For IP, all manipulations were performed at 4°C. Exponentially growing cells (yeast cultures were 
grown and treated as indicated for Yeast Media and Growth Conditions) were harvested by 
centrifugation and resuspended in IP buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl) plus  0.1 % 
Nonidet P-40 (NP40), 1X yeast protease inhibitor cocktail (BioShop), 0.1 mM DTT and 2.5mg/ml 
N-ethylmaleimide), followed by glass bead vortex homogenization for 30 min. Then the lysate 
was centrifuged twice at 3000g for 5 min, and 50µl of the lysate was diluted with an equal volume 
of 2X SDS-PAGE sample buffer (4% sodium dodecyl sulfate [SDS], 20% glycerol, Bromophenol 
Blue, 10% 2-Mercaptoethanol, and 140 mM Tris-HCl pH 8) and boiled for 3 min; the remainder 
was incubated with washed protein G agarose beads (BioShop) and 1 µg of  either rabbit or mouse 
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polyclonal anti-HA epitope tag primary antibody (Cedarlane) overnight at 4˚C . The next day, IPs 
were washed three times with ice-cold IP buffer plus 0.1% NP40, then samples were boiled in SDS 
sample buffer for 3 min at ~95 0C to release protein from the beads. For phosphatase treatment, 
lysates were incubated with 400 U lambda protein phosphatase (NEB) per 50 μL lysate for 15 min 
at 30°C prior to IP 
 
2.5 Antibodies:  
The antibodies for immunoblotting and immunoprecipitation were rabbit and mouse anit-HA (New 
England Biolabs), Smt3 (Santa Cruz), FK1/Ub (Cayman Chemical), Phospho-Ser/Thr/Tyr 
(BioLynx). As secondary antibodies, horseradish peroxidase (HRP)-conjugated anti-rabbit IgG, 
anti-mouse IgG and anti-mouse IgM were used.   
 
2.6 Western Blot: 
Equal amounts of each sample were resolved on a 7.5% SDS-PAGE gel and transferred to 
nitrocellulose membranes (BioShop) followed by incubation with blocking buffer (5% milk in 1x 
PBST [0.05% Tween-20 in 1% PBS (Fisher Scientific)] or TBST [(20mM Tris pH 7.5, 150mM 
NaCl, 0.05% tween -20) ]) for 30 min at room temperature. The membranes were then probed with 
appropriate antibody [HA (1:3000; for detection of HA tagged Gcn4), Smt3 (1:3000; for detection 
of sumoylation), or FK1 (1:1000; for polyubiquitination chain detection)], for overnight at 4˚C. 
Following incubation with the primary antibodies, the membranes were washed 3 times in either 
1x PBST or TBST for 5 min at room temperature. The blots were then incubated with the 
appropriate HRP conjugated secondary antibody (1:5000; Thermo Fisher Scientific) for 30 min at 
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room temperature. The blots were then washed 3 times again and the detection was done by 
chemiluminescence (ECL, Bio-Rad) using autoradiography or a MicroChemi chemiluminescence 
imager (DNR). 
 
2.7 Chromatin immunoprecipitation (ChIP):  
50 mL of SC medium (or selective, as appropriate) was inoculated with appropriate strain at 30˚C 
to an optical density A595 (O.D.) of 0.7-0.8. To induce Gcn4 expression, cultures were treated with 
SM for an appropriate time at a final concentration of 0.5ug/ml, followed by cross-linking with 
1.1% formaldehyde for 20 min, before quenching with 450 mM of glycine for 5 min. Samples 
were pelleted by centrifugation and washed with ice-cold TBS (20mM Tris-HCl, pH 7.5 and 
150mM NaCl), then in ChIP buffer (50 mM HEPES-KOH, pH 7.5, 150 mM NaCl, 1mM EDTA, 
1% Triton X-100, 0.1% sodium deoxycholate and 0.1% SDS). Pelleted samples were then 
resuspended in ChIP buffer and subjected to bead beating with glass beads followed by sonication 
to shear chromatin to fragments of ~500 bp length. Samples were then centrifuged for 5 min, and 
additional NaCl was added to the isolated supernatants to a final concentration of 212.5 mM. Small 
amounts of supernatants (40µL) were stored at -20˚C as Input samples, and the rest of the salt-
adjusted supernatants were incubated for overnight at 4˚C with washed protein G agarose beads in 
addition to 1 µg of the appropriate antibody for IP. The following day, beads were then washed 
first in ChIP buffer with 275mM NaCl, then in ChIP buffer with 500mM NaCl, followed by an 
additional washing buffer (10mM Tris-HCl, pH 8, 0.25M LiCl, 1mM EDTA, 0.5% NP-40 and 
0.5% sodium deoxycholate) and finally with  Tris-EDTA buffer (10mM Tris-HCl, pH 8 and 1mM 
EDTA). [Note: 4 min incubation at room temperature was followed between each washed]. Beads 
were then incubated with ChIP Elution buffer (50mM Tris-HCl, pH 7.5, 10mM EDTA and 1% 
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SDS) for 10min at 65 0C. Samples were then centrifuged at 8000 g and supernatants were treated 
with proteinase K (BioShop) at 42 0C for 1h, and then transferred to 65 0C for 4h to overnight to 
reverse cross-links. The following day, LiCl was added to each sample to a final concentration of 
0.4M and DNA was recovered by phenol–chloroform extraction and ethanol precipitation. Using 
the same experimental condition, each experiment was performed at least three times and the 
average of quantitative PCR (qPCR) analyses are presented using the percent input method, with 
standard deviations shown as error bars.  
For quantification, the signals obtained from the input samples were subtracted from the IPed 
samples, and referred to as normalized ChIP to input. Finally, the “Percent Input” value for each 
sample is calculated as follows: Percent Input = 100*2^(-ΔCt [normalized ChIP to input]). Primer sequences 
used for qPCR are listed in Appendix Table 3. 
 
2.8 RNA isolation and Reverse Transcription-PCR (RT-PCR): 
To extract RNA, 10-mL yeast cultures were grown under appropriate conditions as described 
above. Cultures were treated with SM for 20 min (unless otherwise specified) at a final 
concentration of 0.5 µg/mL to induce Gcn4 expression. Samples were pelleted by centrifugation 
at 3000 g for 3 min at 4°C and washed twice with ice-cold AE buffer (50 mM sodium acetate, pH 
5.2 and 10 mM EDTA, pH 8.0). Pelleted samples were then re-suspended in 400 µL of ice-cold 
AE buffer and 40 µL of 10% SDS was added followed by the addition of 440 µL of phenol (pH 
5.2). Samples were then chilled in a dry ice/ethanol bath (where dry ice was crushed to powder 
and 95% ethanol was added to achieve a thick slurry mixture) for 5 min and then transferred to a 
65°C water bath for 5 min followed by vortex mixing for 30s. After repeating the 
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freeze/thaw/vortex cycle, samples were centrifuged at 16,000 g for 7 min and aqueous layers were 
transferred to fresh micro-centrifuge tubes for standard phenol-chloroform extraction and ethanol 
precipitation of RNA.  
For reverse-transcription, 12 μg samples of RNA were treated with DNase I (New England 
Biolabs) and approximately 1 µg of DNA-free-RNA was used for cDNA synthesis using the Super 
Script II reverse transcriptase reaction (Invitrogen) according to the manufacturer’s instructions. 
For qualitative analysis, one-tenth of the transcripts were used for 24 cycles of standard PCR 
analysis and products were resolved on 2% agarose gels. 
For quantification, qPCR was performed using SYBR Green mix (Froggabio) according to the 
manufacturer’s instructions. Transcripts were normalized to 25S rRNA and calculated by 2-ΔΔCT 
method (Livak and Schmittgen, 2001). All experiments were performed at least three times and 
the average values are presented with standard deviations shown as error bars.  In addition, a two-
tailed Student’s t-test was applied with P-values less than 0.05 (where statistical comparisons were 
performed) indicated as asterisks between relevant samples. Primer sequences are listed in 
Appendix Table 3.  
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Chapter 3: Results 
3.1 Effect of Gcn4 DNA-binding ability on its sumoylation: 
Gcn4, a transcriptional activator, binds specifically to the consensus sequence ‘TGACTC’ of 
amino acid biosynthesis gene promoters as a homodimer (Ellenberger et al. 1992). It was 
previously demonstrated that Gcn4 is sumoylated at two specific Lys residues, K50 and K58, and 
that this modification depends on its ability to bind to target gene promoters (Rosonina et al., 
2012). Therefore, we wished to further study the significance of DNA-binding on Gcn4 
sumoylation. For this, a DNA binding domain (DBD) mutant Gcn4 strain was used which lacks 
the 40 C-terminal amino acids that are required for binding to DNA (Gcn4-∆CT40) (Hope and 
Struhl, 1985; Rosonina et al., 2012). This Gcn4-ΔCT strain was then examined with wild type 
Gcn4 (Gcn4-WT) and SUMO mutant Gcn4 strain (Gcn4-K50,58R), in which two SUMO targeted 
Lys residues, K50 and K58, were substituted with Arg (Rosonina et al., 2012). Expression of Gcn4, 
fused with a C-terminal 6xHA epitope tag in these strains can be induced by treating with 
sulfometuron-methyl (SM), which triggers amino acid starvation in the cells (Rosonina et al., 
2012). The tagged protein is then immunoprecipitated (IPed) with an HA antibody from lysates 
prepared in the presence of the SUMO protease inhibitor N-ethylmaleimide (NEM), followed by 
immunoblot analysis. Consistent with previous findings, we observed a band around ~60kDa for 
Gnc4 although the theoretical molecular weight of the Gcn4 protein with 6xHA epitope tag is 
calculated to be ~ 42 kDa. In addition, we also observed two prominent sumoylated forms of Gcn4 
for Gcn4-WT  in both HA and SUMO immunoblots following IP, which were not observed for 
the Gcn4-K50,58R and Gcn4-ΔCT mutants (asterisks in Figure 10 B; (Rosonina et al., 2012)). 
This suggests that Gcn4 is sumoylated specifically after binding to DNA. 
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Figure 10: Effect of Gcn4 DNA-binding ability on its sumoylation.  (A) The schematic diagram 
of Gcn4 representing probable sites of sumoylation (indicated by encircled S) and the location of 
the 40 C-terminal amino acids (∆CT40) in the DBD necessary for DNA binding. As demonstrated 
previously, Gcn4-6HA migrates at approximately 60 kDa, and each SUMO modification adds 
approximately 12 kDa. (B) Gcn4-WT, Gcn4-K50,58R and Gcn4-∆CT40 strains expressing 6xHA-
tagged Gcn4 were used for HA IPs. Cells were treated with SM (0.5 µg/mL) for 20 min to induce 
Gcn4 expression. IPs were then analyzed by HA (1:3000) and SUMO (1:3000) immunoblots. 
Asterisk (*) indicates the sumoylated forms of Gcn4 visible in HA and SUMO immunoblots. 
 
 
 
A. 
B. 
. 
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Further, to investigate whether directing Gcn4 to a heterologous UAS (upstream activator 
sequence), found upstream of the promoter, could also lead to its sumoylation, the HF7c yeast 
strain was transformed with a plasmid that express a fusion of the Gal4 DNA-binding domain 
(Gal4DB) with the ΔCT truncated form of Gcn4 (Gal4DB-Gcn4ΔCT40). IP-immunoblot analysis 
showed two prominent sumoylated forms in a SUMO IP, indicating that the fusion protein is 
indeed sumoylated (Figure 11). Although the presence of Gal4DB was necessary for sumoylation, 
we did not observe that Gal4DB by itself is sumoylated. Notably, when the Lys residues in the 
Gal4DB-Gcn4-ΔCT40, which corresponded to Gcn4 K50 and K58, were mutated (Gal4DB-Gcn4-
K50,58R-ΔCT40), sumoylation of the fusion protein was ablated, suggesting these residues to be 
the specific sites for Gcn4 sumoylation, whenever it binds DNA (Figure 11). In addition, because 
the Gal4DB-Gcn4ΔCT40 fusion and derivatives were expressed constitutively from the ADH1 
promoter in normally growing HF7c cells without SM treatment Gcn4 sumoylation does not rely 
on amino acid starvation or on the addition of SM. Instead, the data indicates that DNA binding is 
a major prerequisite for Gcn4 sumoylation. 
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Figure 11: Effect of Gcn4 DNA-binding ability on its sumoylation. HF7c cells expressing 
Gal4DB and Gcn4ΔCT40 proteins as well as Gal4DB-Gcn4ΔCT40 and Gal4DB-Gcn4-K50,58R-
ΔCT40 fusion proteins. Gcn4-WT strain expressed wild type Gcn4 protein. All these strains 
contain 6xHA epitope tags. Only Gcn4-WT strain was treated with SM (0.5 µg/mL) for 20 min to 
induce Gcn4 expression. Cell lysates were IPed with monoclonal anti-HA antibody. IPs were then 
analyzed by HA (1:3000) and SUMO (1:3000) immunoblots. Asterisk (*) indicates the Gal4DB 
visible on HA immunoblot. 
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3.2 Coordination of Gcn4 sumoylation and phosphorylation: 
3.2.1 Effects of Gcn4 phosphorylation on its sumoylation  
To elucidate how promoter-associated sumoylation of Gcn4 is associated with its phosphorylation 
by either Pho85 or Cdk8 as part of a regulatory cascade of PTMs, a phosphorylation-site mutant 
(Gcn4-3T2S) Gcn4 strain was generated by altering all five potential Cyclin dependent kinase 
(CDK) target Thr and Ser residues (3T2S) to Ala (Chi et al. 2001). This Gcn4-3T2S strain was 
then examined with Gcn4-K50,58R. When compared to a Gcn4-WT strain, both Gcn4-K50,58R 
and Gcn4-3T2S strains grew normally on amino acid starvation medium (contains SM) suggesting 
that Gcn4 sumoylation and phosphorylation are not essential to initiation of transcription of amino 
acid biosynthesis genes (Appendix Figure 1).  
We then examined the impact of impaired Gcn4 phosphorylation on its sumoylation using Gcn4-
WT, Gcn4-K50,58R, and Gcn4-3T2S strains. IP-immunoblot analysis demonstrated that the 
phosphorylation mutant form of Gcn4 strain is subject to normal sumoylation (Figure 12). This 
result indicates that Gcn4 phosphorylation is not necessary prior to its sumoylation.  
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Figure 12: Effect of Gcn4 phosphorylation on its sumoylation. HA and SUMO immunoblot 
analysis of IPs from indicated yeast strains expressing 6xHA-tagged Gcn4. Cells were treated with 
SM (0.5 µg/mL) for 20 min to induce Gcn4 expression. IPs were then analyzed by HA (1:3000) 
and SUMO (1:3000) immunoblots. Asterisk (*) indicates the sumoylated form of Gcn4 visible in 
HA immunoblots. 
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3.2.2 Effect of Gcn4 sumoylation on its phosphorylation 
In order to examine whether Gcn4 sumoylation affects its subsequent phosphorylation, we 
attempted to detect phosphorylated forms of IPed Gcn4 and Gcn4-K50,58R using a general 
phospho-Ser/Thr/Tyr antibody. However, no signal was detected, indicating that this approach 
would not succeed (data not shown). Instead, we used immunoblotting conditions that allowed us 
to resolve phosphorylated and unphosphorylated isoforms of Gcn4 on an HA immunoblot, without 
the need for phospho-specific antibodies. Such conditions had already been used to detect 
phosphorylated forms of in-vitro translated Gcn4 (Chi et al., 2001). Therefore, phosphatase 
analysis was performed with Gcn4-WT and Gcn4-K50,58R strains, where extracts were treated 
with Lambda protein phosphatase. Untreated Gcn4-WT and Gcn4-K50,58R extracts were also 
included as controls, and the phosphatase treated and untreated samples were analyzed side by side 
on an HA immunoblot. Treatment with phosphatase revealed that, sumoylated Gcn4 is also 
phosphorylated (compare lanes 1 and 2 in Figure 13), and, like Gcn4-WT, Gcn4-K50,58R is 
normally subject to different levels of phosphorylation (compare doublets in lanes 1 and 3 with 
lanes 2 and 4, respectively). However, the Gcn4-K50,58R sample showed an elevated abundance 
of the least phosphorylated form compared to Gcn4-WT (lowest band), suggesting that 
sumoylation can stimulate some level of Gcn4 phosphorylation (e.g. the increased abundance in 
this form might correspond to Gcn4 that would otherwise be sumoylated and phosphorylated; 
compare lanes 1 and 3 in Figure 13). Similar results were observed when the analysis was 
performed in a strain lacking Pho85 (pho85∆ gcn4- 6xHA and pho85∆ gcn4-6xHA-
K50,58R),which suggests that Cdk8 is responsible for generating the specific phosphorylated 
forms of Gcn4 detected in this assay (lanes 5-8 in Figure 13). Together, this analysis suggests that, 
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although sumoylation is not a requirement for Gcn4 phosphorylation, blocking Gcn4 sumoylation 
does alter its overall phosphorylation. 
 
 
Figure 13: Effect of Gcn4 sumoylation on its phosphorylation. HA immunoblot analysis of 
extracts from Gcn4-WT and Gcn4-K50,58R strains expressing HA-tagged. Cells were treated with 
SM (0.5 µg/mL for 20 min) for Gcn4 induction. Indicated lysates were subsequently treated with 
Lambda phosphatase at 30 0C for 15 min, and were then analyzed by HA (1:3000) immunoblot.  
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3.3  Coordination of Gcn4 sumoylation and ubiquitination: 
3.3.1 Effects of Gcn4 ubiquitination on its sumoylation  
To study how promoter-associated sumoylation of Gcn4 is coordinated with its ubiquitination, we 
used a yeast strain in which Gcn4 ubiquitination is blocked by mutation of the Gcn4 ubiquitin 
conjugating enzyme Cdc34 (cdc34-2) (Appendix Figure 2A). This strain was previously used to 
demonstrate the role of  Gcn4 ubiquitination on its degradation and transcriptional activity 
(Meimoun et al., 2000). The cdc34-2 strain displayed moderate growth defects when grown under 
amino acid starvation conditions, although normal growth was observed under normal conditions 
(Appendix Figure 2B). Gcn4-WT, Gcn4-K50,58R, and cdc34-2 strains were analyzed by IP 
followed by immunoblotting, which demonstrated that Gcn4 that is not ubiquitinated is subject to 
virtually normal SUMO modification. Therefore, this result indicates that Gcn4 sumoylation is not 
dependent on its prior ubiquitination (Figure 14).  
 
Figure 14: Effect of Gcn4 ubiquitination on its sumoylation. Analysis of HA IPs obtained from 
SM-induced cells expressing HA tagged Gcn4-WT, cdc34-2 and Gcn4-K50,58R strains. IPs were 
analyzed by HA (1:3000) and SUMO (1:3000) immunoblots.  
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3.3.2 Effect of Gcn4 sumoylation on its ubiquitination 
In order to study the effect of impaired Gcn4 sumoylation on its ubiquitination, Gcn4-WT, Gcn4-
K50,58R  and Gcn4-3T2S strains were treated with MG132, to inhibit proteolysis by the 26S 
proteasome, followed by SM to induce Gcn4 expression. As expected, immunoblot analysis with 
a ubiquitin antibody (FK1) did not display ubiquitinated forms of Gcn4 in the Gcn4-3T2S strain 
because Gcn4 phosphorylation is required for its ubiquitination (Lipford et al., 2005). However, a 
smear of ubiquitinated forms of Gcn4 was observed for both Gcn4-WT and Gcn4-K50,58R strains 
(Figure 15; right). This result indicates that the bulk of Gcn4 ubiquitination is not dependent on 
its prior sumoylation. 
 
 
Figure 15: Effect of Gcn4 sumoylation on its ubiquitination. HA (1:3000) and Ub (1:1000) 
immunoblots analysis of IPs from Gcn4-WT, Gcn4-3T2S  and Gcn4-K50,58R strains expressing 
HA-tagged treated with MG132 ((75μM for 45 min) followed by SM induction (0.5 µg/mL for 20 
min).  
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However, Gcn4 is normally phosphorylated by two different CDKs, Pho85 and Cdk8, and prior 
phosphorylation is required for its efficient ubiquitination  (Meimoun et al. 2000; Chi et al. 2001; 
Shemer et al. 2002). Therefore, we explored the relationship between sumoylation and specifically 
Cdk8-mediated ubiquitination of Gcn4 using Pho85-deleted Gcn4-WT and Gcn4-K50,58R strains. 
As controls, we also included Pho85-containing Gcn4-WT and Gcn4-K50,58R strains. As shown 
in Figure 16A, fewer modified forms of Gcn4 were detected in the pho85∆ Gcn4-WT and Gcn4-
K50,58R cells compared to the Pho85-containingcells, reflecting the dependence on Pho85 for the 
bulk of Gcn4 ubiquitination. Nonetheless, Pho85-independent, MG132-stabilized forms of Gcn4 
were detected in the Gcn4-WT strain, but not in the Gcn4-K50,58R strain (Figure 16A and 16B). 
Together, these results demonstrate that there is no co-dependence of sumoylation and 
ubiquitination in Pho85-containing yeast, and that most Gcn4 modifications are dependent on the 
Pho85 pathway. However, our results point to a role for sumoylation in Pho85-independent 
ubiquitination of Gcn4, which is consistent with a model in which sumoylation triggers Cdk8 
phosphorylation-mediated ubiquitination of Gcn4. 
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Figure 16: Effect of Gcn4 sumoylation on its ubiquitination. Analysis of MG132 ((75μM for 
45 min) and SM treated (0.5 µg/mL for 20 min) Pho85 containing or deleted Gcn4-WT and Gcn4-
K50,58R strains expressing 6xHA-tagged Gcn4. (A) IPs were analyzed by HA (1:3000) 
immunoblot. (Left panel: light exposure; Right panel: long exposure of the same blot). (B) HA 
immunoblot (1:3000) analysis of MG132 treated and untreated extracts from pho85 deleted Gcn4-
WT and Gcn4-K50,58R strains expressing HA-tagged. 
  
B. A. 
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3.4 Effect of Gcn4 activation on its sumoylation:  
The activation domain (AD) of Gcn4 functions through a short conserved sequence motif, and 
seven hydrophobic residues (F97, F98, M107, L113, W120, L123 and F124) are reportedly 
essential for its function in activating transcription (Drysdale et al., 1995; Brzovic et al., 2011; 
Warfield et al., 2014). Using its AD, Gcn4 binds to coactivators which lead to the formation of the 
pre-initiation complex on target gene promoters, which enables transcription. To study whether 
promoter-associated sumoylation of Gcn4 is dependent on its ability to activate transcription, we 
first generated a strain in which the Trp 120 residue of the Gcn4 AD was substituted with Ala 
(W120A). Based on the results of previous mutational studies, we predicted that this mutant strain 
(Gcn4-W120A) would be deficient in target gene activation (Brzovic et al., 2011; Warfield et al., 
2014). However, Gcn4-W120A was able to grow under amino acid starvation conditions, which 
indicate that the mutation is not activation deficient (Figure 17). A series of additional mutant 
strains were then generated, where each of the key hydrophobic residues were mutated in various 
combinations. However, all of these strains were also able to grow under amino acid starvation 
conditions (Figure 17). Furthermore, RT-PCR was performed with these strains to analyze mRNA 
levels of Gcn4-dependent amino acid starvation induced genes ARG1 and CPA2 and a 
constitutively expressed gene, PMA1. As shown in Figure 18A, all of these mutants were 
transcriptionally active. This suggests that transcriptional activation by Gcn4 is complex and not 
restricted to a single region of an AD. Not surprisingly, IP-immunoblot analysis indicated that all 
of these mutant strains are targets of normal sumoylation (Figure 18B). Further analysis will be 
required to examine a possible dependence of Gcn4 sumoylation on its ability to activate 
transcription. 
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Figure 17: Effect of Gcn4 activation on its sumoylation. (A) The schematic diagram of Gcn4 
representing probable sites of sumoylation (indicated by encircled S) and the activation domain 
(AD). (B) Spot assay comparing the growth of indicated strains. Cells were serially diluted and 
spotted on synthetic medium lacking Ura, Val and Ile (Left) and the same medium containing the 
indicated level of SM (1x is 0.5µg/mL), and incubated for 5 days at 30 0C.   
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Figure 18: Effect of Gcn4 activation on its sumoylation. (A) RT-PCR analysis of SM induced 
genes (ARG1 and CPA2) and a control gene (PMA1). 25S refers to internal control 25S rRNA. 
(B) HA (1:3000) and SUMO (1:3000) immunoblots analysis of IPs from indicated yeast strains 
expressing 6xHA-tagged Gcn4. Cells were treated with SM (0.5 µg/mL for 20 min) to induce Gcn4 
expression.  
  
B. 
 
A. 
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3.5 Effect of RNAP II recruitment on Gcn4 sumoylation  
Gcn4 is a target for efficient sumoylation specifically after binding to target gene promoters, but 
it is not clear whether its sumoylation is dependent on ongoing transcription by RNAP II (Rosonina 
et al., 2012). Therefore, to examine the effect of ongoing transcription, specifically RNAP II 
recruitment, on Gcn4 sumoylation, Gcn4 was tagged with 6xHA in a strain that harbors a 
temperature sensitive allele of RNA polymerase II, rpb1-1 (Nonet et al., 1987). Rpb1 is the largest 
subunit of RNAP II with a unique C-terminal domain (CTD) which plays crucial roles in 
transcription (Phatnani and Greenleaf, 2006). At elevated temperatures (~37°C), RNAP II is 
inactivated in this strain causing the rpb1-1 Gcn4 strain to display growth defects at non-
permissive temperatures (39°C) (Figure 19A). Gcn4-WT and rpb1-1 strains were grown at normal 
(28˚C) or restrictive (39˚C) temperatures and treated with or without SM. mRNA levels of amino 
acid starvation induced genes (ARG1, CPA2 induced by SM) and a constitutively expressed gene 
(PMA1; as a control) were then analyzed by RT-PCR. As expected, Gcn4 target gene expression 
was reduced in rpb1-1 cells compared to Gcn4-WT at both the permissive and non-permissive 
temperatures (Figure 19B, top & middle). Using the same experimental conditions, IP-
immunoblot analysis was performed with Gcn4-WT and rpb1-1 cells. As shown in the figure 18C, 
rpb1-1 cells displayed Gcn4 sumoylation even at non-permissive temperatures suggesting that 
ongoing transcription is not required for Gcn4 sumoylation (Figure 19C, right). 
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Figure 19: Effect of RNAP II recruitment on Gcn4 sumoylation. (A) Spot assay comparing 
growth of Gcn4-WT and rpb1-1 strains on synthetic medium lacking uracil at the indicated 
temperature. (B) RT–PCR analysis of amino acid induced genes ARG1, CPA2, and a constitutively 
expressed gene PMA1. As an internal control, 25S rRNA was also analyzed. Gcn4-WT and rpb1-
1 Gcn4 strains were grown at 28°C until they reached an exponential phase. They were then 
transferred to either 28°C or 39°C for 15 mins followed by SM treatment (indicated as “+”) for 15 
min. (C) HA and SUMO immunoblot analysis of IPs. Cells were grown and treated as mentioned 
in (B).  
A. B. 
C. 
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To address the possibility that elevated temperature itself triggered Gcn4 sumoylation in the 
experiment described above, an additional method was used to block transcription and examine 
Gcn4 sumoylation. We obtained a previously reported Rbp1 Anchor Away strain, in which 
RNAPII can be conditionally and rapidly removed from nuclei in living yeast cells, by adding 
rapamycin to the growth medium (Haruki et al., 2008). By this system, Rpb1 is fused to the FRB 
domain of human mTOR in a yeast strain expressing RPL13A-FKBP12, a fusion of ribosomal 
protein RpL13A and human FKBP12, which binds FRB in the presence of rapamycin. Upon 
addition of rapamycin to the growth medium, FRB will bind to FKBP12 causing the Rpb1-FRB 
fusion to exit the nucleus with RPL13A, which will eventually block transcription without the need 
of elevated temperatures. For this analysis, we tagged Gcn4 with 6xHA in Rpb1-FRB strains 
(obtained from Kevin Struhl’s lab) and the cells were grown in non-induced and induced 
conditions in the presence or absence of rapamycin as indicated in Figure 20. Immunoblotting 
with a SUMO antibody further supports our finding that Gcn4 is sumoylated in the absence of 
nuclear Rpb1 (Figure 20, right). Therefore, it can be concluded that on-going transcription is not 
necessary for promoter-bound Gcn4 sumoylation. 
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Figure 20: Effect of RNAP II recruitment on Gcn4 sumoylation. Analysis of HA and SUMO 
immunoblot using Rpb1-FRB fusion Gcn4 strain, where cells were treated with 1µg/mL 
rapamycin (indicated by “+” sign) for 20 min followed by 20 min treatment with SM (indicated 
by “+” sign) at a final concentration of 0.5ug/ml. 
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3.6 Effect of hyper-sumoylated Gcn4 on its promoter occupancy  
As demonstrated above and previously, Gcn4 becomes sumoylated specifically after binding to 
target gene promoters, and this facilitates its removal from DNA (Rosonina et al., 2012). To further 
elucidate the significance of sumoylation on Gcn4 function, a “permanently sumoylated” form of 
Gcn4 fusion strain was generated (Gcn4-Smt3). In this fusion strain, the SUMO gene (SMT3) was 
inserted to the GCN4 locus, such that an N-terminal SUMO fusion form of Gcn4 could be 
generated, leading it to be constitutively sumoylated. Although this continuously sumoylation 
form did not affect the strain’s normal growth and viability (Appendix Figure 3A), it exhibited a 
significantly higher level of sumoylation compared to the Gcn4-WT (Appendix Figure 3B, right), 
allowing us to determine the effects of hyper-sumoylation of Gcn4. 
To analyze the impact of higher levels of Gcn4 sumoylation on the expression of its target genes, 
an RT-qPCR analysis was performed. We found that Smt3-Gcn4 fusion cells generated 
significantly fewer Gcn4 activated ARG1 and CPA2 transcripts compared to Gcn4-WT, while no 
significant difference was observed for a constitutively expressed gene that is not regulated by 
Gcn4 such as PMA1 (Figure 21A). We then performed ChIP assays to compare the levels of Gcn4-
WT and Smt3-Gcn4 cells on the promoter of the target gene ARG1 over a time course of amino 
acid starvation. As seen in Figure 21B, significantly lower levels of Smt3-Gcn4 were detected on 
the ARG1 promoter compared to Gcn4-WT (10 and 15 min post induction). These findings suggest 
that a high level of Gcn4 sumoylation is associated with lower levels of target gene activation and 
strongly supports our hypothesis that sumoylation stimulates the removal of Gcn4 from promoters. 
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Figure 21: Effect of hyper-sumoylation of Gcn4 on its promoter occupancy. (A) mRNA levels 
of Gcn4-WT and Smt3-Gcn4 cells were determined by RT–PCR for amino acid starvation induced 
genes ARG1, CPA2 and a control housekeeping gene, PMA1, with or without SM. Values were 
normalized to 25S rRNA. Data are represented as mean +/- SD of three independent experiments. 
(B) ChIP analysis of Gcn4-WT and Smt3-Gcn4 cells on ARG1 promoter at indicated times after 
SM induction. Data are represented as mean +/- SD of three independent experiments. 
 
 
A. B. 
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We then wanted to study whether deletion of CDK8 can reverse the effects of hyper-sumoylation 
of Gcn4 on expression of target genes to provide further evidence that Cdk8 is involved in removal 
of sumoylated Gcn4 from target promoters (Rosonina et al., 2012). For this, we deleted CDK8 in 
the Smt3-Gcn4 fusion strain (cdk8∆Smt3-Gcn4) and compared target gene induction and promoter 
occupancy with a Cdk8-containing strain. In otherwise wild-type cells, deletion of CDK8 resulted 
in reduced expression of ARG1 suggesting that Cdk8 normally plays a positive role in regulating 
RNAP II transcription (Figure 22A).  However, we observed that the deletion of CDK8 in cells 
expressing the Smt3-Gcn4 fusion protein at least partly reversed the effects of hyper-sumoylation 
of Gcn4 on expression of target genes. This was indicated by the significant increase in expression 
of ARG1 compared to CDK8 containing Smt3-Gcn4 fusion cells (Figure 22B). Consistent with 
this, significantly higher levels of Smt3-Gcn4 was detected on the ARG1 promoter when Cdk8 was 
absent (10 and 15 min post induction; Figure 23). Taken together with our previous findings, these 
findings strongly support the idea that Gcn4 sumoylation triggers its removal from target DNA in 
a manner dependent on its subsequent phosphorylation by Cdk8. 
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Figure 22: Effect of hyper-sumoylation of Gcn4 on its promoter occupancy. mRNA levels 
were determined by RT–PCR for amino acid starvation induced gene ARG1, and a control 
housekeeping gene, PMA1, with or without treatment with SM (0.5ug/ml for 20 min). Values were 
normalized to 25S rRNA. Data are represented as mean +/- SD of three independent experiments 
with * p <  0.05. (A) Analysis was performed with strains expressing Gcn4-WT and cdk8∆ Gcn4. 
(B) Analysis was performed with strains expressing Gcn4-WT, Smt3-Gcn4 and cdk8∆Smt3- Gcn4. 
  
A. B. 
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Figure 23: Effect of hyper-sumoylation of Gcn4 on its promoter occupancy. ChIP analysis of 
Smt3-Gcn4 and Cdk8∆ Smt3-Gcn4 fusion cells occupancy on ARG1 promoter at indicated times 
after SM induction. Data are represented as mean +/- SD of three independent experiments. 
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Chapter 4: Discussion 
Post-translational modifications (PTMs) can have a profound impact on the function, subcellular 
localization and stability of a protein. There are numerous PTMs that a protein can undergo. Gcn4, 
a transcriptional activator of amino acid biosynthesis genes, is subjected to multiple protein PTMs, 
including phosphorylation, ubiquitination and sumoylation. Studies revealed that Gcn4 possesses 
two consensus sumoylation sites (K 50, 58) (Rosonina et al., 2012). In addition, it contains five 
potential sites (S17, T61, T105, T165 and S218) for phosphorylation, catalyzed by two specific 
CDKs: Pho85 and Cdk8. Pho85 phosphorylates Gcn4 regardless of whether it is promoter-bound 
or not, while Cdk8, a component of the Mediator complex, phosphorylates specifically promoter-
bound Gcn4 (Chi et al. 2001; Meimoun et al. 2000). In both pathways, phosphorylation targets 
Gcn4 for ubiquitination and subsequent degradation through the 26S proteasome (Lipford et al., 
2005). However, the crosstalk between different PTMs, especially between sumoylation, 
phosphorylation and ubiquitination, remains unclear. To address this, the purpose of this study was 
to understand how Gcn4 sumoylation is dependent on its binding to DNA, and how this 
modification is coordinated with its phosphorylation and ubiquitination as part of a regulatory 
cascade of PTMs.  
To accomplish this, we first investigated whether Gcn4 sumoylation was affected by preventing 
binding to target gene promoters using a Gcn4 DNA-binding domain mutant yeast strain, and 
determining whether its sumoylation could be restored when fused to a heterologous DNA binding 
domain. In order to study whether Gcn4 phosphorylation and ubiquitination levels were affected 
by blocking its sumoylation, a yeast strain that expresses a sumoylation-deficient mutant form of 
Gcn4 (Gcn4-K50,58R) was used. Conversely, the effect of impaired Gcn4 phosphorylation and 
ubiquitination on its sumoylation was examined using phosphorylation-site mutant and 
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ubiquitination impaired Gcn4 strains. We then attempted to generate a series of transcriptional 
activation mutant Gcn4 strains to study whether Gcn4 sumoylation is affected by its ability to 
activate its target genes. However, none of the mutants displayed a detectable reduction in target 
gene activation. Further, we analyzed the effect of ongoing transcription, specifically RNAP II 
recruitment, on Gcn4 sumoylation using a temperature sensitive RNAP II mutant Gcn4 strain as 
well as utilizing an alternative approach, the ‘Anchor away’ technique (Haruki et al. 2008). Finally, 
using a “permanently sumoylated” form of Gcn4 fusion strain, we further demonstrated that 
sumoylation acts to facilitate Gcn4 removal from target promoters, after it has acted in 
transcriptional activation. 
Gcn4 binds to target gene promoters as a homodimer, and this specific DNA binding activity 
resides in the 56 C-terminal amino acids that facilitates both dimerization and promoter 
recognition, a region that folds independently of the rest of the protein  (Hope & Struhl 1986; 
Struhl 1987; Ellenberger et al. 1992). Employing immunoprecipitation assays, we showed that 
although Gcn4 becomes sumoylated specifically after binding to target gene promoter, its efficient 
phosphorylation by either Pho85 or Cdk8 is not a prerequisite for this PTM. This was indicated by 
the lack of a significant difference in the level of sumoylation between Gcn4-WT and 
phosphorylation impaired Gcn4 protein. We also observed that SUMO-mutant Gcn4 is 
phosphorylated by both CDKs, but SUMO-deficient Gcn4 displays an increase in the least 
phosphorylated form of Gcn4 compared to Gcn4-WT. We observed this effect in both Pho85-
containing yeast, as well as in a Pho85-deleted background where promoter-bound Gcn4 can only 
be phosphorylated by Cdk8. Therefore, it could be concluded that even though most modifications 
are dependent on the Pho85 pathway, some Cdk8-mediated Gcn4 phosphorylation (and subsequent 
modifications) are likely stimulated by its sumoylation. Consistent with this finding, we also 
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observed that the level of Gcn4 ubiquitination detected in pho85Δ cells disappears in cells 
expressing SUMO-deficient Gcn4, suggesting that Cdk8-mediated ubiquitination of Gcn4 is 
stimulated by its sumoylation. In addition, we did not observe Gcn4 ubiquitination in the 
phosphorylation mutant Gcn4 strain, which further supports prior studies that phosphorylation is 
required for ubiquitin-mediated Gcn4 degradation (Meimoun et al. 2000; Shemer et al. 2002).  
Mutagenesis studies previously demonstrated that the Gcn4 activation domain functions through 
a short conserved sequence motif, and that seven hydrophobic residues are essential for its 
transcriptional activation function. When these residues are mutated in combination, it can perturb 
activation  (Drysdale et al., 1995; Brzovic et al., 2011; Warfield et al., 2014). Therefore, we 
attempted to generate a transcriptional activation mutant Gcn4 strain by altering these hydrophobic 
residues without affecting Gcn4 sumoylation and DNA binding ability in order to analyze the 
effect of transcriptional activation on Gcn4 sumoylation. Unfortunately, although we were able to 
generate the mutant strains, none of them displayed a deficiency in Gcn4 activation, as determined 
by induction of Gcn4 target genes, and growth on amino acid starvation medium. 
However, by using a temperature sensitive RNAP II mutant strain and employing 
immunoprecipitation assays, we showed that on-going transcription, specifically RNAP II 
recruitment, is not essential for promoter-bound Gcn4 sumoylation. In addition, to avoid 
ambiguities regarding the effect of high temperature (37°C) on Gcn4 sumoylation, we used the 
Rpb1-FRB fusion strain, in which RNAPII can be conditionally removed from nuclei upon 
addition of rapamycin, which further supports our finding that transcription is not required for 
Gcn4 sumoylation. 
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To further explore the role of Gcn4 sumoylation, we generated a SUMO fusion version of Gcn4 
and, employing RT-PCR and ChIP assays, we observed that hyper-sumoylation of Gcn4 is 
associated with less target gene activation and reduced occupancy of Gcn4 on target promoters. 
Furthermore, the Smt3-Gcn4 fusion strains displayed significantly higher levels of ubiquitination 
than Gcn4-WT (Appendix Figure 4). However, the increased ubiquitination detected on the Smt3-
Gcn4 fusion was abolished by deletion of CDK8, which further support the involvement of Cdk8 
in clearing sumoylated Gcn4 from target promoters by stimulating its ubiquitination and 
degradation (Appendix Figure 4). Consistent with our findings, we also observed that deletion of 
CDK8 can partly reverse the effects of hyper-sumoylation of Gcn4 on expression and occupancy 
of target genes.  
   
Taken together, the results of our experiments led us to propose a model depicted in Figure 24. 
According to the model, Gcn4 becomes sumoylated after binding to the target gene promoter. 
Indeed, our study demonstrates that DNA binding appears to be the only critical determinant of 
Gcn4 sumoylation. Although it is still not clear whether sumoylation is dependent on the efficient 
recruitment of general transcription factors (i.e. activation), it is evident that ongoing transcription, 
specifically RNAP II recruitment, is not necessary for sumoylation. Further, SUMO modification 
of Gcn4 stimulates Cdk8-dependent phosphorylation, which then targets Gcn4 for ubiquitination 
and subsequent degradation through the 26S proteasome. The promoter can then be shut down or 
additional, unbound Gcn4 molecules can then bind to it, permitting subsequent rounds of 
transcription. 
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Although some questions still remain unanswered in this model, the investigation of the 
coordination of PTMs on promoter-bound Gcn4 shed significant light on the multiple intricate 
mechanisms by which the cell regulates an important transcription factor. 
 
 
Figure 24: A proposed model for regulation of promoter-bound Gcn4 by Cdk8-
phosphorylation dependent, ubiquitin-mediated degradation. [1] Unmodified Gcn4 binds to 
the promoter. [2] Promoter-bound Gcn4 may (or might not) recruit transcription complexes 
including Cdk8, Ubc9 (the SUMO E2 conjugation enzyme) and SUMO to activate target 
promoters; Ubc9 then sumoylates Gcn4, and [3] this modification specifically activates the Cdk8 
phosphorylation-mediated pathway, [4,5] which targets Gcn4 for ubiquitination and subsequent 
degradation through the 26S proteasome.  
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Future Directions: 
Future investigations as a continuation of this work will focus on the sumoylation of individual 
Lys residues to determine whether sumoylation of either Lys 50 or 58 alone is sufficient to affect 
promoter-associated Gcn4 phosphorylation and ubiquitination. For this, strains expressing Gcn4 
mutated at either Lys 50 or 58 (to non-sumoylatable Arg) will be tested by using IP-immunoblot 
and time-course ChIP analyses. 
In addition, it would be interesting to investigate whether sumoylation influences Gcn4 occupancy 
time at a target promoter by using competition ChIP, which has previously been used to measure 
turnover rates of promoter-associated transcription factors Rap1 and TBP (Werven et al., 2009: 
Lickwar et al., 2012). By this method, a yeast strain will be generated that harbors constitutively 
expressed HA-tagged Gcn4 and inducible Flag-tagged Gcn4 that is either WT or SUMO mutant. 
Once induced, the ability of the Flag-tagged SUMO mutant to exchange with WT HA-Gcn4 on a 
target gene promoter will  be determined over a time-course by ChIP with Flag and HA antibodies. 
Slower exchanges rates in the SUMO mutant compared to WT Gcn4 will indicate that sumoylation 
acts to reduce Gcn4 residence time on target promoters. Using the same method, the role of 
ubiquitination in controlling Gcn4 occupancy time at a target promoter should also be analyzed.  
Regardless of the existing data, it is still unknown whether Cdk8-dependent phosphorylation and 
ubiquitination of Gcn4 exclusively depends on its ability to bind to gene promoters. To test for 
this, strain expressing Gcn4-6HA that is unable to bind to DNA, in a pho85Δ background, where 
Cdk8 is the major Gcn4 kinase, will be examined using IP-immunoblot assays after phosphatase 
analysis, which we already  employed to resolve phosphorylated and unphosphorylated isoforms 
of Gcn4-6HA on an HA immunoblot. 
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Finally, the influence of transcriptional activation on Gcn4 sumoylation should be investigated 
further by obtaining an activation impaired Gcn4 strain. This is an especially challenging approach 
as the objective is to obtain a strain which is impaired in recruiting transcription factors while 
preserving other characteristics like 3D structure, folding, DNA binding and PTMs like 
sumoylation. Although various studies prepared differernt Gcn4 activation mutant strains, they 
were mostly dissimilar to our approach as they were not concerned about keeping the 
aforementioned characteristics intact (Drysdale et al., 1995; Brzovic et al., 2011; Warfield et al., 
2014). For instance, Drysdale et al. (1995) deleted amino acid residues 18-169 to obtain an 
activation mutant strain without considering the effects of blocking residues important for other 
functions. This includes residues K50 and 58, both known sites for sumoylation. 
 Some preliminary attempts were conducted with different combinations of mutations (already 
mentioned in the results section), albeit with unsuccessful results. Future attempts will focus on 
obtaining a mutant strain by deleting/substituting various amino acid residues in different 
combinations so as not to impede other functions. A successful activation mutant should ideally 
not have the residues necessary for co-activator binding as well as activation. This mutant strain 
should then be tested by spot assay to see if it really is activation deficient. Upon successful 
confirmation, ChIP assay should then be performed to determine whether this AD mutant Gcn4 
strain is still capable of binding to DNA. If it is capable to binding to DNA, it will then be tested 
by using IP-immunoblot with Smt3 antibody to determine whether it gets sumoylated. 
These future research goals will provide more insight into the role of sumoylation in regulation of 
promoter-bound Gcn4, and as a result a better understanding of the crosstalk between different 
PTMs that are with sumoylation and relationships between them. 
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Appendix: 
Table 1: S. cerevisiae strains used in this study  
Strains Genotype 
ERYM 055 Wild type without any tag 
ERYM 079 HF7c 
ERYM 613 Wild type Gcn4 with 6 HA tag 
ERYM 631 gcn4Δ::kanMX [p GCN4-6HA /CEN URA3] 
ERYM 663 gcn4Δ::kanMX [pGCN4-6HA/CEN URA3] 
ERYM 664F gcn4Δ::kanMX [pGCN4- 6 HA -K50,58R /CEN URA3] 
ERYM 665 gcn4∆::NATr pho85∆::kanMX [pGCN4-6HA/CEN URA3] 
ERYM 666 gcn4∆::NATr pho85∆::kanMX [pGCN4-K50,58R-6HA/CEN URA3]  
ERYM 667 gcn4∆::NATr srb10∆::kanMX [pGCN4-6HA/CEN URA3]  
ERYM 671 gcn4∆::NATr srb10∆::kanMX pho85∆::LEU2 [pGCN4-6HA / CEN URA3] 
ERYM 709 gcn4∆::kanMX [pGCN4-6HA-∆Cterminal40/CEN URA3] 
YAA 001 cdc4-1 GCN4-6HA::kl TRP1 
YAA 002 cdc34-2 GCN4-6HA::kl TRP1 
YAA 003 gcn4Δ::kanMX [pGCN4-3T2S-6HA / CEN URA3] 
YAA 010 gcn4Δ::kanMX [pGCN4-6HA/URA3 CEN] 
YAA 011 gcn4Δ::kanMX rpb1-1 [pGCN4-6HA/ CEN URA3] 
YAA 013 pGcn4-W120A / CEN URA3 
YAA 029 cdc34-2 GCN4-6HA [Prs316 / CEN URA] 
YAA 030H SMT3-GCN4-6HA::Kl TRP1 
YAA 031 gcn4Δ::kanMX [p-Gcn4-W120A, Δ(129-126) /CEN URA3] 
YAA 032 pGcn4-6HA RPB1-FRB Anchor Away strain 
YAA 033 gcn4Δ::kanMX [pGcn4-F97,98R, W120A, Δ(123-126)-6HA / CEN URA3] 
YAA 034 SMT3-GCN4-6HA::Kl TRP1 cdk8Δ::KanMX6 
YAA 035 gcn4Δ::kanMX [pGcn4-M107A Y110A L113A W120A Δ(123-126)-6HA/CEN URA3] 
YAA 036 gcn4Δ::kanMX [pGcn4- F97,98A M107A Y110A L113A W120A] 
YAA 038 gcn4Δ::kanMX [pGCN4-flag /CEN URA3] RPB1-FRB Anchor Away strain] 
YAA 039 gcn4Δ::kanMX [pGCN4-6HA / CEN URA3] gal11Δ::KanMX6] 
YER 026 HF7c  [pGalDB-Gcn4ΔCT-6HA] 
70 
 
Strains Genotype 
YER 027 HF7c [pGalDB-6HA] 
YER 028 HF7c [pGalDB-Gcn4ΔCT-K50,58R-6HA] 
YER 029 HF7c [pGcn4ΔCT-6HA] 
 
 
Table 2: Primers used for activation mutant Gcn4 strains  
Mutant Strains Direction         Sequence ( from 5’ to 3’) 
 
W120A 
Sense CCTAGAAGACAACTCTAAAGAAGCGACATCCTTGTTTGAC 
Anti-sense TTCTTTAGAGTTGTCTTCTAGGTTTTCATACTCAAAC 
 
W120A 
∆123-126 
Sense TCTAAAGAAGCGACATCCATTCCAGTTACCACTGACG 
Anti-sense GGATGTCGCTTCTTTAGAGTTGTCTTCTAGGTTTTCATACTC 
F97,98R W120A 
∆123-126 
Sense GCTGTAGTGGAATCTGCCGCGTCGTCAAGCACTGAT 
Anti-sense AGATTCCACTACAGCGTCATCTAGCTCCGG 
M107A Y110A 
W120A ∆123-
126 
Sense TCAAGCACTGATTCAACTCCAGCGTTTGAGGCCGAAAACGCG
GAAGACAACTCTAAA  
Anti-sense TGGAGTTGAATCAGTGCTTGACGAAAAGAAAGATTCCACTAC 
M107A Y110A 
F97,98R W120A 
∆123-126 
Sense TCAAGCACTGATTCAACTCCAGCGTTTGAGGCCGAAAACGCG
GAAGACAACTCTAAA  
Anti-sense TGGAGTTGAATCAGTGCTTGACGAAAAGAAAGATTCCACTAC 
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Table 3: Primers used for qPCR (ChIP and RT-PCR) 
Target Gene Region        Primer Sequence ( from 5’ to 3’) Direction 
 
ARG1 
 
Promoter 
 
GACGGCTCTCCAGTCATTTAT Sense 
TTCCATACGGCACCGTTAAT Anti-sense 
ARG1 ORF 
ACGGTACTGTCAGGGTTAGA Sense 
GGTGGTATCGGTAGGTAAGAAAC Anti-sense 
 
CPA2 ORF 
 
GCTGCTGAAAGGGTCAAATAC Sense 
 AAACCTGAGCCTAACCCACCCAAA Anti-sense 
 
PMA1 
 
ORF 
CTGGTCCATTCTGGTCTTCTATC Sense 
TCAGACCACCAACCGAATAAG Anti-sense 
 
25S 
 
ORF 
TCTAGCATTCAAGGTCCCATTC Sense 
CCCTTAGGACATCTGCGTTATC Anti-sense 
 
 
 
 
Appendix Figure 1: Characterization of SUMO-mutant and phosphorylation impaired 
Gcn4. Spot assay for comparison of growth of the indicated strains. Strains were serially diluted 
and spotted on synthetic medium lacking Ura, Val and Ile (top) and the same medium containing 
0.5 μg/mL SM (bottom), and incubated for 3 days at 30 °C. 
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Figure 2: Characterization of ubiquitin mutant Gcn4. (A) Immunoblots analysis of IPs from 
Gcn4-WT and ubiquitin-impaired Gcn4 cells treated with MG132 ((75μM for 45 min) followed 
by SM induction (0.5 µg/mL for 20 min). IPs were then analyzed by anti-HA (1:1000) and anti- 
poly Ub (1:1000) antibodies.  (B) Spot assay for comparison of growth of the indicated strains. 
Cells were serially diluted and spotted on synthetic medium lacking Ura, Val and Ile (top) and the 
same medium containing 0.5µg/mL SM (bottom), and incubated for 3 days at 30 0C. 
 
 
 
 
 
A. 
B. 
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Figure 3: Characterization of hyper-sumoylated Smt3-Gcn4 fusion strain. (A) Spot assay for 
comparison of growth of the indicated strains. Strains were serially diluted and spotted on synthetic 
medium lacking Ura, Val and Ile (top) and the same medium containing 0.5µg/mL SM (bottom), 
and incubated for 3 days at 30 0C. (B) HA and SUMO immunoblots analysis of IPs from indicated 
yeast strains. Cells were treated with SM (0.5 µg/mL for 20 min) to induce Gcn4 expression.  
 
 
 
 
 
 
A. B. 
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Figure 4: Characterization of hyper-sumoylated Smt3-Gcn4 fusion strain. A) Immunoblots 
analysis of IP’s from Gcn4-WT, SUMO-fusion and cdk8 deleted SUMO-fusion Gcn4 strains 
treated with MG132 ((75μM for 45 min) and SM (0.5 µg/mL for 20 min) IPs were then analyzed 
by anti-HA (1:1000) and anti- poly Ub (1:1000) antibodies.   
 
